Clinical Trial Update: Phase I/II Study of Anti-Mucin1 (MUC1) CAR T Cells for Patients With MUC1+ Advanced Refractory Solid Tumor [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial evaluating Anti-Mucin1 (MUC1) CAR T cells in patients with MUC1-positive advanced refractory solid tumors across several cancer types.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma
• Non-small Cell Lung Cancer
• Pancreatic Cancer
• Triple-negative Breast Cancer

Drugs mentioned

• Anti-Mucin1 (MUC1) CAR T Cells (MUC1-targeted CAR T cells)

Snippet

Sponsor: PersonGen BioTherapeutics (Suzhou) Co., Ltd. | Conditions: Hepatocellular Carcinoma, Non-small Cell Lung Cancer | Phase 1, Phase 2 | Status: UNKNOWN